Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-649-3530
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.56 million
Profitability
Miscellaneous
Employees232
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions
What is Coherus Biosciences' stock symbol?
Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus Biosciences' earnings last quarter?
Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.10. View Coherus Biosciences' Earnings History.
When is Coherus Biosciences' next earnings date?
What price target have analysts set for CHRS?
5 brokers have issued 1-year target prices for Coherus Biosciences' shares. Their predictions range from $25.00 to $45.00. On average, they anticipate Coherus Biosciences' stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.
What is the consensus analysts' recommendation for Coherus Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.
What are Wall Street analysts saying about Coherus Biosciences stock?
Here are some recent quotes from research analysts about Coherus Biosciences stock:
- 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (5/15/2019)
- 2. Maxim Group analysts commented, "CHRS shares are trading up ~12% on better than expected preliminary 1Q19 net sales of $36M-$38M for UDENYCA (initial launch 1/3). These initial figures suggest that uptake is progressing, in our view, faster than anticipated considering consensus estimates for FY19 were ~$70M-$80M as of the 4Q18 earnings call (2/28/19). The company will provide greater detail on its 1Q19 earnings call scheduled for 5/9/19." (4/8/2019)
Has Coherus Biosciences been receiving favorable news coverage?
News articles about CHRS stock have been trending negative on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Coherus Biosciences earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Coherus Biosciences' key competitors?
Some companies that are related to Coherus Biosciences include argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX) and Regenxbio (RGNX).
What other stocks do shareholders of Coherus Biosciences own?
Who are Coherus Biosciences' key executives?
Coherus Biosciences' management team includes the folowing people:
- Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
- Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
- Dr. Peter K. Watler, Chief Technical Officer (Age 57)
- Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
- Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)
Who are Coherus Biosciences' major shareholders?
Coherus Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.70%), BlackRock Inc. (6.57%), FMR LLC (5.95%), Rubric Capital Management LP (3.81%), Geode Capital Management LLC (1.01%) and Northern Trust Corp (0.96%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Institutional Ownership Trends for Coherus Biosciences.
Which major investors are selling Coherus Biosciences stock?
CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rubric Capital Management LP, Wellington Management Group LLP, BlackRock Inc., Pier Capital LLC, Morgan Stanley, Citigroup Inc. and Platinum Investment Management Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Barbara K Finck, James Healy and Jean-Frederic Viret. View Insider Buying and Selling for Coherus Biosciences.
Which major investors are buying Coherus Biosciences stock?
CHRS stock was bought by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Sivik Global Healthcare LLC, Goldman Sachs Group Inc., Atika Capital Management LLC, Rhenman & Partners Asset Management AB, Fosun International Ltd, Geode Capital Management LLC and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Coherus Biosciences.
How do I buy shares of Coherus Biosciences?
Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus Biosciences' stock price today?
One share of CHRS stock can currently be purchased for approximately $20.16.
How big of a company is Coherus Biosciences?
Coherus Biosciences has a market capitalization of $1.40 billion and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.
What is Coherus Biosciences' official website?
How can I contact Coherus Biosciences?
Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]
MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
